Join Us at Booth N5M07 | November 12–14, 2025 | Chongqing International Expo Center
Tianming Pharmaceutical Group is proud to announce our participation in the 93rd China International Pharmaceutical Raw Materials, Intermediates, Packaging, and Equipment Trade Fair (API China).
The event will be held from November 12 to 14, 2025, at the Chongqing International Expo Center. We warmly invite all our global partners, customers, and industry peers to visit us at Booth N5M07.
Founded with a strong commitment to innovation and quality, Tianming Pharmaceutical Group has become a leading manufacturer of pharmaceutical intermediates and active pharmaceutical ingredients (APIs).
With years of experience in research, development, and large-scale production, we specialize in providing high-quality intermediates for therapeutic areas such as cardiovascular, anti-diabetic, and anti-tumor drugs.
Our state-of-the-art facilities operate under strict GMP standards, ensuring that every product meets global pharmaceutical quality requirements. We serve a wide range of customers across Asia, Europe, and North America, and are continuously expanding our partnerships through technology innovation and reliable supply capabilities.
API China is one of the most influential exhibitions in the pharmaceutical industry, connecting global manufacturers, researchers, and buyers. Visiting Tianming’s booth provides an excellent opportunity to:
We believe face-to-face communication is the foundation of lasting partnerships, and we look forward to sharing how Tianming’s professional expertise can support your pharmaceutical development goals.
Email: sunqian0123@gmail.com
WhatsApp: +86 176 6371 3557
We Look Forward To Your Visit!
Why more pharma companies outsource intermediate manufacturing is no longer just a cost question. Based on real project experience, this article explains how outsourcing intermediates helps drug developers improve speed, manage impurity risk, and maintain regulatory control while focusing on core innovation.
This article shares practical, field-based experience on designing robust analytical methods for complex intermediates, focusing on impurity identification, method robustness, and regulatory expectations.
The Rise of High-Potency Intermediates highlights a fundamental shift in pharmaceutical manufacturing, where potency-related risks emerge early at the intermediate stage. As oncology and targeted therapies expand, manufacturers must integrate exposure control, impurity strategy, and scalable process design to ensure compliance, safety, and long-term supply reliability.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.